- Home
- M vs ORKA Comparison
M vs ORKA Comparison
Compare M & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | ORKA |
|---|---|---|
| Founded | 1830 | 2004 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Department/Specialty Retail Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 2003 | 1997 |
Fundamental Metrics
Financial Performance| Metric | M | ORKA |
|---|---|---|
| Price | $23.37 | $109.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $20.09 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 4.5M | 768.5K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 12.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $103.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.66 | $14.08 |
| 52 Week High | $26.59 | $109.42 |
Technical Indicators
Market Signals| Indicator | M | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 73.49 |
| Support Level | $22.32 | $82.34 |
| Resistance Level | $24.50 | N/A |
| Average True Range (ATR) | 0.82 | 5.50 |
| MACD | -0.22 | 0.94 |
| Stochastic Oscillator | 12.95 | 99.96 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.